|
1
|
Döhner K and Döhner H: Molecular
characterization of acute myeloid leukemia. Haematologica.
93:976–982. 2008.
|
|
2
|
Beghini A, Peterlongo P, Ripamonti CB, et
al: C-kit mutations in core binding factor leukemias. Blood.
95:726–727. 2000.
|
|
3
|
Dombret H, Preudhomme C and Boissel N:
Core binding factor acute myeloid leukemia (CBF-AML): is high-dose
Ara-C (HDAC) consolidation as effective as you think? Curr Opin
Hematol. 16:92–97. 2009.
|
|
4
|
Heinrich MC, Blanke CD, Druker BJ and
Corless CL: Inhibition of KIT tyrosine kinase activity: a novel
molcular approach to the treatment of KIT-positive malignancies. J
Clin Oncol. 20:1692–1703. 2002.
|
|
5
|
Roskoski R Jr: Structure and regulation of
Kit protein-tyrosine kinase - the stem cell factor receptor.
Biochem Biophys Res Commun. 338:1307–1315. 2005.
|
|
6
|
Mrózek K and Bloomfield CD: Chromosome
aberrations, gene mutations and expression changes, and prognosis
in adult acute myeloid leukemia. Hematology Am Soc Hematol Educ
Program. 169–177. 2006.
|
|
7
|
Nanri T, Matsuno N, Kawakita T, et al:
Mutations in the receptor tyrosine kinase pathway are associated
with clinical outcome in patients with acute myeloblastic leukemia
harboring t(8;21)(q22;q22). Leukemia. 19:1361–1366. 2005.
|
|
8
|
Schnittger S, Kohl TM, Haferlach T, Kern
W, Hiddemann W, Spiekermann K and Schoch C: KIT-D816 mutations in
AML1-ETO-positive AML are associated with impaired event-free and
overall survival. Blood. 107:1791–1799. 2006.
|
|
9
|
Corless CL, Harrell P, Lacouture M, et al:
Allele-specific polymerase chain reaction for the
imatinib-resistant KIT D816V and D816F mutations in mastocytosis
and acute myelogenous leukemia. J Mol Diagn. 8:604–612. 2006.
|
|
10
|
Fuster O, Barragán E, Bolufer P, et al:
Rapid detection of KIT mutations in core-binding factor acute
myeloid leukemia using high-resolution melting analysis. J Mol
Diagn. 11:458–463. 2009.
|
|
11
|
Sotlar K, Escribano L, Landt O, et al:
One-step detection of c-kit point mutations using peptide nucleic
acid-mediated polymerase chain reaction clamping and hybridization
probes. Am J Pathol. 162:737–746. 2003.
|
|
12
|
Paschka P, Marcucci G, Ruppert AS, et al;
Cancer and Leukemia Group B. Adverse prognostic significance of KIT
mutations in adult acute myeloid leukemia with inv(16) and t(8;21):
a Cancer and Leukemia Group B Study. J Clin Oncol. 24:3904–3911.
2006.
|
|
13
|
Huang Q, Liu Z, Liao Y, et al: Multiplex
fluorescence melting curve analysis for mutation detection with
dual-labeled, self-quenched probes. PloS One. 6:e192062011.
|
|
14
|
Vardiman JW, Thiele J, Arber DA, et al:
The 2008 revision of the World Health Organization (WHO)
classification of myeloid neoplasms and acute leukemia: rationale
and important changes. Blood. 114:937–951. 2009.
|
|
15
|
Higuchi R, Krummel B and Saiki RK: A
general method of in vitro preparation and specific mutagenesis of
DNA fragments: study of protein and DNA interactions. Nucleic Acids
Res. 16:7351–7367. 1988.
|
|
16
|
Heckman KL and Pease LR: Gene splicing and
mutagenesis by PCR-driven overlap extension. Nat Protoc. 2:924–932.
2007.
|
|
17
|
Kohl TM, Schnittger S, Ellwart JW,
Hiddemann W and Spiekermann K: KIT exon 8 mutations associated with
core-binding factor (CBF)-acute myeloid leukemia (AML) cause
hyperactivation of the receptor in response to stem cell factor.
Blood. 105:3319–3321. 2005.
|
|
18
|
Frost MJ, Ferrao PT, Hughes TP and Ashman
LK: Juxtamembrane mutant V560GKit is more sensitive to Imatinib
(STI571) compared with wild-type c-kit whereas the kinase domain
mutant D816VKit is resistant. Mol Cancer Ther. 1:1115–1124.
2002.
|
|
19
|
Wang YY, Zhou GB, Yin T, et al: AML1-ETO
and C-KIT mutation/overexpression in t(8;21) leukemia: implication
in stepwise leukemogenesis and response to Gleevec. Proc Natl Acad
Sci USA. 102:1104–1109. 2005.
|
|
20
|
Lück SC, Russ AC, Du J, et al: KIT
mutations confer a distinct gene expression signature in core
binding factor leukaemia. Br J Haematol. 148:925–937. 2010.
|
|
21
|
Paschka P, Marcucci G, Ruppert AS, et al;
Cancer and Leukemia Group B. Adverse prognostic significance of KIT
mutations in adult acute myeloid leukemia with inv(16) and t(8;21):
a Cancer and Leukemia Group B Study. J Clin Oncol. 24:3904–3911.
2006.
|
